Polyclonal antibodies were prepared against synthetic peptides corresponding to four different extramembrane segments of the rat glucagon receptor. The antibodies bound specifically to native glucagon receptor as judged by immunofluorescence microscopy of cultured cells expressing a synthetic gene for the receptor. Antibodies to peptides designated PR-15 and DK-12 were directed against amino acid residues 103-117 and 126-137, respectively, of the extracellular N-terminal tail. Antibody to peptide KD-14 was directed against residues 206-219 of the first extracellular loop, and antibody to peptide ST-18, against the intracellular Cterminal tail, residues 468-485. The DK-12 and KD-14 antibodies, but not the PR-15 and ST-18 antibodies, could effectively block binding of 1251-labeled glucagon to its receptor in liver membranes. Incubation of these antibodies with rat liver membranes resulted in both a decrease in the maximal hormonal binding capacity and an apparent decrease in glucagon affinity for its receptor. These effects were abolished in the presence of excess specific peptide antigen. In addition, DK-12 and KD-14 antibodies, but not antibodies, interfered with glucagon-induced adenylyl cyclase activation in rat liver membranes and behaved as functional glucagon antagonists. These results demonstrate that DK-12 and KD-14 antibodies are pharmacologically active glucagon antagonists and strongly suggest that residues 126-137 of the N-terminal tail and residues 206-219 of the first extracellular loop contain determinants of ligand binding and may comprise the primary ligand-binding site on the glucagon receptor.
liver membranes. Incubation of these antibodies with rat liver membranes resulted in both a decrease in the maximal hormonal binding capacity and an apparent decrease in glucagon affinity for its receptor. These effects were abolished in the presence of excess specific peptide antigen. In addition, DK-12 and KD-14 antibodies, but not PR-15 and ST- 18 antibodies, interfered with glucagon-induced adenylyl cyclase activation in rat liver membranes and behaved as functional glucagon antagonists. These results demonstrate that DK-12 and KD-14 antibodies are pharmacologically active glucagon antagonists and strongly suggest that residues 126-137 of the N-terminal tail and residues 206-219 of the first extracellular loop contain determinants of ligand binding and may comprise the primary ligand-binding site on the glucagon receptor.
The glucagon receptor belongs to a unique group within a larger family of seven-helix transmembrane receptors that are coupled to one or more intracellular signaling pathways via heterotrimeric guanine nucleotide-binding proteins (G proteins) (1, 2) . Members of the glucagon receptor group include receptors for secretin (3) , glucagon-like peptide 1 (GLP-1) (4), vasoactive intestinal peptide (VIP) (5) , and growth hormonereleasing factor (6) . The receptors have a relatively large extracellular N-terminal tail thought to be involved in hormone-receptor interaction (Fig. 1) . By mechanisms not yet understood, the signal of hormone binding is conveyed from the cell surface across the transmembrane domain to activate G proteins on the cytoplasmic surface.
Peptide antagonists of glucagon have been developed that effectively compete for receptor sites and have defined several chemical features of the peptide ligand that affect receptor binding and activation (7) (8) (9) . However, little is known about the corresponding hormone interaction sites on the receptor that regulate recognition and specificity and trigger postbinding biochemical events leading to the biological effect.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked Seven putative transmembrane helices based on previous models of G protein-coupled receptors are shown. The N terminus and extracellular surface are toward the top, and the C terminus and cytoplasmic surface are toward the bottom of the figure. The locations of the amino acid segments that were used to design the peptides for antibody production are labeled PR-15, DK-12, KD-14, and ST-18 and are not drawn to scale. The peptide sequences are given in Table 1. A gene encoding the rat glucagon receptor was synthesized and expressed (10, 11) . By use of this expression system, an N-terminal deletion mutant and five truncation mutants were prepared to delineate the protein domains required for binding and subsequent transmission of the hormonal message to intracellular effectors (12) . Amino acid residues 20-115 were deleted from the N-terminal tail to provide a mutant receptor without asparagine-linked glycosylated sites. In addition, portions of the C terminus of the receptor were progressively truncated to provide two forms of the receptor protein with a shortened cytoplasmic tail and three smaller mutants that consisted of the N terminus followed by one, three, or five transmembrane helices. Results from binding competition studies of these mutants were consistent with the notion that an intact N terminus and contributions from the extracellular loops connecting the transmembrane helices were required for glucagon binding. In contrast, most of the C-terminal tail was not important for ligand binding or 
MATERIALS AND METHODS
Preparation of Antibodies to Glucagon Receptor Peptides. Pentadecapeptide PR-15 (receptor residues 103-117), dodecapeptide DK-12 (receptor residues 126-137), and tetradecapeptide KD-14 (receptor residues 206-219) were assembled stepwise by the Merrifield solid-phase method (13) as previously described for peptide ST-18 (receptor residues 468-485) (11) . The peptides were cleaved from the polymer support, analyzed by HPLC and by amino acid analysis, and used without further purification. Rabbits were immunized following peptide conjugation to keyhole limpet hemocyanin (11, 14) . Antibody titer was initially monitored by immunoblot analysis of liver plasma membranes subjected to SDS/PAGE. All crude anti-peptide antisera were affinity purified on a column of peptide antigen coupled to agarose (Affi-Gel 15; Bio-Rad), and the affinity-purified antibodies were desalted and concentrated in phosphate-buffered saline, pH 7.4 (Microcon-10; Amicon), before storage at -20°C. Antibody protein concentration was determined by UV absorbance at 278 nm, with rabbit IgG as a standard. bound. Membrane aliquots were tested for sequence-specific reactivity by preincubation for 2 hr at 4°C with various concentrations of antibody in the absence or presence of 25 ,tM peptide immunogen, followed by competitive binding with 1251-glucagon as described above. As a standard for each assay, a parallel set of membrane samples was also preincubated under the same conditions, followed by continued incubation after the addition of radioligand (0.5 nM) and serial dilutions of unlabeled glucagon. Results were expressed as a percentage of the total 125I-labeled glucagon bound to membranes alone versus the logarithm of glucagon or antibody concentration.
Under analogous conditions, inhibition of 125I-glucagon binding by and KD-14 in membranes of COS-1 cells after transfection with a synthetic glucagon receptor gene was also assayed (11) . All experiments were performed at least three times with duplicate determinations.
Inhibition of Hormone-Stimulated Adenylyl Cyclase. The effect of the antibodies on glucagon-stimulated cAMP production was determined by allowing various concentrations of each antibody to compete with a constant concentration of glucagon. Aliquots of liver membrane suspension containing 10,tg of protein were preincubated for 2 hr at 4°C with various concentrations of antibody in 25 mM Tris.HCl/0.1% BSA, pH 7.4. The mixtures were then incubated for 10 min at 37°C with a constant glucagon concentration (23 nM) in a final assay volume of 100 ,l that contained, in addition, 25 mM MgCl2, 0.025 mM GTP, 5 mM ATP, 0.9 mM theophylline, 17.2 mM creatine phosphate, and creatine kinase at 1 mg/ml. The reaction was terminated by immersing the samples in a boiling water bath for 3 min. The membrane protein was pelleted by centrifugation, and 50 ,ul aliquots of the supernatant fractions were assayed for the presence of cAMP (Amersham). In a parallel experiment, the ability of DK-12 or KD-14 antibody to mimic glucagon-induced adenylyl cyclase activation was also tested and compared with the natural glucagon-dosedependent cyclase response in liver membranes. Plasma membrane aliquots were incubated with various amounts of DK-12 or KD-14 antibody, and the cAMP produced was determined.
Data for the stimulation of adenylyl cyclase were expressed as percent of maximal cAMP accumulation per milligram of membrane protein and plotted against the logarithm of antibody concentration. The ratio of the concentration of antibody to glucagon when the response was reduced to 50% of the response to 23 nM glucagon in the absence of antibody is the inhibition index, I/A50. The pA2 value (17) , calculated from the dose-response curve, is the negative logarithm of the concentration of ligand that reduces the response of 1 unit of agonist to that of 0.5 unit of agonist.
Enzyme-Linked Immunosorbent Assay (ELISA) of Antipeptide Antibodies. Reactivity of the purified antibodies with the synthetic peptide antigens and with glucagon was determined by ELISA (18) .
Immunofluorescence Microscopy of Transfected COS-1 Cells Expressing Glucagon Receptor. The method used for the imaging of transiently transfected COS-1 cells was previously described (12) . All images shown in Fig. 5 were photographed at 1000-fold magnification.
RESULTS
Preparation of Anti-peptide Antibodies. Peptides corresponding to preselected sequences from the rat glucagon receptor were synthesized. PR-15 and DK-12 were derived from amino acid positions 103-117 and 126-137 of the Nterminal tail, KD-14 from positions 206-219 of the first extracellular loop, and ST-18, from the extreme C-terminal tail, positions 468-485. Fig. 1 illustrates the topological location of these peptide epitopes on the receptor. Antibodies were raised in rabbits against each conjugated peptide and affinity purified. The antibodies are designated PR-15, DK-12, KD-14, and ST-18. The DK-12 and ST-18 antibodies were previously shown by immunoblot analysis to bind specifically to the glucagon receptor expressed in COS-1 cells (11, 12) . The DK-12 antibody was also used in an immunofluorescence microscopy study of site-directed receptor mutants (12) . Effect of Antibodies on 125I-Glucagon Binding to Receptors in Liver Membranes. Preincubation of rat liver membranes with each of the affinity-purified antibody preparations was followed by continued incubation with 1251-glucagon. Inhibition of 125I-labeled glucagon binding to liver membrane receptors in the presence of increasing concentrations of DK-12, KD-14, PR-15, or ST-18 antibody or rabbit IgG is shown in Fig.  2 . The DK-12 and KD-14 antibodies blocked glucagon binding in a concentration-dependent manner. The bindingdisplacement curves for both DK-12 and KD-14 fit well to the same logistic function that described glucagon binding (Fig. 2) .
The concentration of antibody required to inhibit 50% of 1251-glucagon binding (IC50 value) was determined from curve fits of multiple independent experiments to be 37 10 nM (mean ± SE, n = 5) for DK-12 and 45 ± 23 nM (n = 4) for KD-14 (Table 1) .
Under the same conditions, PR-15 or ST-18 antibody or purified rabbit IgG did not compete significantly with 1251-glucagon binding to receptor sites in liver membranes. Sequence specificity of the inhibitory effect was demonstrated by the observation that the inhibition of 125I-glucagon binding by both DK-12 and KD-14 antibodies was completely reversed in the presence of their respective peptide immunogen (Fig. 2) (Fig. 4) . SAKTSLASSLPRLADSPT (468-485) *Numbers refer to the amino acid position in the rat glucagon receptor (see Fig. 1 ).
tConcentration of antibody required to displace 50% of receptor-bound glucagon (see Fig. 2 ). For DK -12 antibody, 37 nM was the mean of five independent determinations with a standard error of 10 log concentration, M Inhibition of Glucagon-Stimulated Adenylyl Cyclase Activity. Each antibody was also assayed for its ability to inhibit glucagon-dependent adenylyl cyclase activity. The increase in intracellular cAMP produced in liver membranes was determined when a constant amount of glucagon (23 nM) was incubated alone or with increasing concentrations of antibody. The cAMP increase induced by 23 nM glucagon was progressively reduced to near-basal levels by both DK-12 and KD-14 antibodies (data not shown). The concentration of inhibitor required to decrease the response of 23 nM glucagon to 50% was 0.8 ,tM DK-12 antibody and 1.4 ,uM KD-14 antibody, which corresponded to inhibition indices (I/A5s) of 34 and 61, and pA2 values of 6.9 and 6.8, respectively (Table 1) . The presence of PR-15 or ST-18 antibody did not alter the agonist response elicited by glucagon (data not shown).
ELISA. To test the antibodies for reactivity to their peptide antigens as well as for crossreactivity toward glucagon, an ELISA was performed. The purified antipeptide antibodies bound to their respective peptide antigens, and none of the four antibodies reacted with glucagon (data not shown).
Immunofluorescence Microscopy of Transfected COS-1 Cells. Evidence for the specificity of the antibodies to the native glucagon receptor was demonstrated by immunofluorescence microscopy of transiently transfected COS-1 cells. PR-15, DK-12, and KD-14 antibodies, produced against extracellular epitopes, generated a positive fluorescent signal when incubated with cells transfected with an expression vector containing the synthetic receptor gene under nonpermeabilizing and permeabilizing conditions (Fig. 5) . In contrast, ST-18 antibody, which was raised against an intracellular epitope, gave a positive signal only under permeabilizing conditions which permit entry of the primary and secondary antibodies into the cells. Cells transfected with the expression vector not containing the glucagon receptor gene were not stained (data not shown). These results show that the antibodies recognize their specific epitopes, since the expressed receptors are known to be transported to the cell surface (12 (Fig. 1) . Immunofluorescence microscopy using antibody was previously reported (12) . (X 1000.) 
DISCUSSION
Four polyclonal antibodies were produced against peptides with unique sequences preselected from the rat glucagon receptor protein (Fig. 1) (Fig. 3) . The glucagon-binding curves also shifted to the right with increasing antibody concentration (data not shown), which is characteristic of a lowering of agonist-binding affinity. In addition, competitive behavior was shown by the antagonist-like response of the antibodies in causing attenuation of glucagon-induced accumulation of cAMP in liver membranes. Indeed, like typical glucagon antagonists (7, 9) , the antibody-receptor complex did not stimulate adenylyl cyclase activity (Fig. 4) .
Although it is clear that the DK-12 and KD-14 antibodies inhibit glucagon binding by binding to the glucagon receptor, the exact nature of the competition cannot be specified. It is possible that antibody binding causes an effect at a distance, such as steric interference, that prevents glucagon binding. However, the PR-15 antibody, which binds to amino acids [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] of the N-terminal tail, had no effect on glucagon binding, whereas the DK-12 antibody, which binds to amino acids 126-137, inhibited glucagon binding. Thus, the PR-15 and DK-12 antibody epitopes seem to delimit a putative glucagon-binding domain that includes at least the N-terminal tail of the receptor distal to position 117. The antibody results indicate that the region spanning residues 206-219 in the first extracellular loop is also a component of the glucagonbinding domain.
A composite of recent findings utilizing glucagon/GLP-1 receptor chimeras (27) , secretin/VIP receptor chimeras (28), and glucagon receptor mutants (12) also suggests that the glucagon-binding domain may consist primarily of a discontinuous domain that encompasses residues proximal to the point at which the first transmembrane segment begins and includes the first extracellular loop. Other interhelical loops and transmembrane domains are required for proper membrane transport and are likely to provide intraprotein or protein-ligand contacts that stabilize the agonist-bound conformation of the receptor (12) .
The DK-12, KD-14, and PR-15 antibodies, raised against extracellular epitopes, gave a positive signal upon immunofluorescence microscopy of COS-1 cells transfected with a synthetic glucagon receptor gene, under both nonpermeabilizing and permeabilizing conditions, but not on untransfected cells (Fig. 5) (12) . As expected, the ST-18 antibody, raised against an intracellular epitope, produced a positive signal only under permeabilizing conditions (Fig. 5) (12) . Although proteins may be partially denatured during the mild fixation procedure, the results indicate that the extracellular epitopes are exposed on the cell surface and are therefore likely to be accessible to antibody or hormone in membrane preparations or in vivo.
Systematic structure-function analysis through the chemical synthesis of peptide analogues has led to potent glucagon antagonists (9, 29) . The next step in the rational design of antagonists is the identification of residues in the glucagon receptor that participate directly in ligand binding and dictate strict binding specificity. Further studies employing molecular biology and chemical synthesis are required to verify these potential ligand-receptor interactions.
